Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allergovac Depot SCIT for HDM Allergic Rhinoconjunctivitis
NCT02881879Phase 1Completed
- Sponsor
- ROXALL Medizin GmbH
- Start
- Jul 2016
- Primary completion
- Sep 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allergovac depot in allergic rhinoconjunctivitis (ARC), sponsored by ROXALL Medizin GmbH. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 5 months. Started Jul 2016; status: completed.
02
Drugs
allergovac depot
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT02881879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02881879.